KT-621
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Asthma
Conditions
Eosinophilic Asthma
Trial Timeline
Jan 28, 2026 → Dec 1, 2027
NCT ID
NCT07323654About KT-621
KT-621 is a phase 2 stage product being developed by Kymera Therapeutics for Eosinophilic Asthma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07323654. Target conditions include Eosinophilic Asthma.
What happened to similar drugs?
6 of 17 similar drugs in Eosinophilic Asthma were approved
Approved (6) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07323654 | Phase 2 | Recruiting |
| NCT07217015 | Phase 2 | Recruiting |
| NCT06945458 | Phase 1 | Completed |
Competing Products
20 competing products in Eosinophilic Asthma